Cancer drug marches toward filing

Share this article:

Merrimack Pharmaceuticals said today that its candidate for metastatic pancreatic cancer, MM-398, in combination with 5-FU and leucovorin, met its primary endpoint and will be submitted to the FDA in 2014. The agency granted MM-398 an orphan drug designation for metastatic pancreatic cancer in 2011.

MM-398+5-FU+leucovorin saw an overall survival of 6.1 months, representing a 1.9-month improvement over the 4.2 months of survival demonstrated by a control arm of 5-FU+leucovorin alone. MM-398, on its own, did not demonstrate a statistically significant survival advantage, though.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters